Price$42.94+4.44 (+11.53%)
2026-03-042026-06-05
News · 26 weeks63-36%
2025-12-142026-06-07
Mix3290d
- SEC Filings20(63%)
- Other7(22%)
- Analyst4(13%)
- Earnings1(3%)
Latest news
25 items- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- SECSEC Form SD filed by Novo Nordisk A/SSD - NOVO NORDISK A S (0000353278) (Filer)
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- PRPeptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness MarketsNEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The market for peptide-based health and performance products has been growing fast as more consumers focus on fitness, recovery, longevity, weight management, and overall wellness. Peptides are being widely explored for areas tied to muscle recovery, metabolic health, anti-aging research, and performance optimization. What used to be a niche biotech category is now attracting attention from wellness brands, pharmaceutical companies, and investors looking for exposure to one of the faster-growing areas of healthcare innovation. Those seeking high-growth opportunities in wellness and biotech should watch these c
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- PRThe $59B Quiet Shift Reshaping How Patients Access CareIssued on behalf of VentriPoint Diagnostics Ltd.Equity-Insider.com News CommentaryVANCOUVER, BC, May 12, 2026 /CNW/ -- Point-of-care diagnostics just crossed $58.76 billion globally in 2026, growing at nearly 10% annually as testing that used to require a hospital lab now fits on a clinic counter or a patient's nightstand[1]. That capital rotation is real: digital health startups pulled in $4 billion in Q1 alone, the strongest first quarter since the pandemic peak, with average deal sizes at levels not seen since late 2021[2]. Investors are not chasing drug discovery this cycle; they are backing companies that can deliver clinical-grade results through faster, lighter, cheaper channels, and
- PRPeptide Wellness Market Could Near $300 Billion as Consumer Demand AcceleratesNEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary -- Investor interest in the next-generation wellness market is picking up fast as peptide-based health and performance products become more mainstream. More consumers are looking for wellness solutions that go beyond traditional supplements — products designed to support energy, recovery, metabolism, healthy aging, fitness, and overall well-being. As people become more focused on taking control of their health earlier in life, demand for science-backed peptide products continues to grow, creating major opportunities for companies developing high-quality formulations and modern wellness platforms. Investors looki
- PRThe Next Generation of the GLP-1 Revolution Is Already UnderwayAUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Obesity and type 2 diabetes mellitus (T2DM) have become two of the most pressing healthcare challenges worldwide, driving rising rates of cardiovascular disease, fatty liver disease, kidney complications and escalating healthcare costs. What began as a niche class of diabetes medications has evolved into one of the most transformative therapeutic categories in modern medicine, with GLP-1 receptor agonists now reshaping obesity treatment, metabolic care and potentially even neurodegenerative disease management. Against this backdrop, SureNano Science Ltd. (CSE:SURE) (OTCQB:SURNF), (profile) through its subsidiary
- PRBiotech's Next Wave May Already be in MotionDENVER, May 07, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com and NeOnc Technology) - The biotech and pharma sector is entering one of its most pivotal periods in years, where insider conviction, late-stage clinical wins, and platform technologies are converging to reshape both valuations and patient outcomes. From aggressive insider buying ahead of critical data to blockbuster Phase 3 readouts redefining entire therapeutic categories, the market is signaling that the next cycle of winners may already be taking shape. At the center of this narrative sits a lesser-known but increasingly watched name: NeOnc Technologies (NASDAQ:NTHI), a company whose leadership is making a bold, highly vi
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- PRThe Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation TrialIssued on behalf of Avaí Bio, Inc. Companies mentioned in this commentary include: Avaí Bio, Inc. (OTCQB:AVAI), Eli Lilly and Company (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Viking Therapeutics, Inc. (NASDAQ:VKTX), Longeveron Inc. (NASDAQ:LGVN). Key Takeaways: The global anti-aging market generated more than $85 billion in 2025 and is projected to approach $120 billion by 2030, with private investment in longevity science more than doubling to $8.49 billion across 325 deals last year.The U.S. FDA approved 50 new drugs in 2024 and 46 in 2025 — including what researchers are calling the first drug class of "longevity therapeutics" — while big pharma spent more than $65 billion acquiring bi
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- ANALYSTWolfe Research initiated coverage on Novo Nordisk A/SWolfe Research initiated coverage of Novo Nordisk A/S with a rating of Peer Perform
NVO FAQ
6 questionsWhat does Novo Nordisk A/S do?
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop...Where does NVO stock trade?
Novo Nordisk A/S (NVO) is listed on NYSE.What sector and industry is NVO in?
Novo Nordisk A/S operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about NVO?
Novo Nordisk A/S has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Peer Perform on 2026-03-26. Recent price targets range from $4000.00 to $4200.00.What companies are similar to NVO?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare NVO side-by-side with any of them on Quantisnow.How can I track NVO on Quantisnow?
Quantisnow aggregates Novo Nordisk A/S's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NVO to receive live email and push alerts on every new disclosure.